SCN4A: Sodium channel protein type 4 subunit alpha
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Pore-forming subunit of Nav1.4, a voltage-gated sodium (Nav) channel that directly mediates the depolarizing phase of action potentials in excitable membranes.
- Drugs that act on it: 3
- With a US drug page: 2
- Type: Protein
Drugs That Act on It
Approved and clinical-stage drugs ChEMBL records for this target; those with a US approval link to their page| Levobupivacaine | Approved | Sodium channel protein type IV alpha subunit blocker | Blocker | — |
| Ranolazine | Approved | Sodium channel protein type IV alpha subunit blocker | Blocker | — |
| Bupivacaine | — | Sodium channel protein type IV alpha subunit blocker | Blocker | Boxed warning |
Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Paramyotonia congenita of Von Eulenburg
- 0.84
- Hyperkalemic periodic paralysis
- 0.83
- Potassium-aggravated myotonia
- 0.81
- Hypokalemic periodic paralysis, type 2
- 0.74
- Congenital myopathy 22B, severe fetal
- 0.74
- Congenital myasthenic syndrome
- 0.70
- Hypokalemic periodic paralysis
- 0.70
- Congenital myasthenic syndrome 16
- 0.69
- Seizure
- 0.69
- Pain
- 0.67
- Congenital myopathy 22A, classic
- 0.66
- Epilepsy
- 0.61
Genes and Related Targets
Complexes and families that share a gene with this target- Genes
- SCN4A
- Related
- Sodium channel alpha subunit
Drugs and mechanisms are from ChEMBL CHEMBL2072 (CC BY-SA 3.0). Gene name, function (UniProt P35499, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets